Evidence map›Paper›PMID 41917404›Full record

ArticleAdvances in experimental medicine and biology2026

Glycoconjugate Vaccines Against Nosocomial Klebsiella pneumoniae Infections.

Feng-Ling Yang, Shih-Hsiung Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Feng-Ling YangInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
Shih-Hsiung WuInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan. shwu@gate.sinica.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Klebsiella pneumoniae (KP) is a critical gram-negative opportunistic pathogen, causing not only nosocomial infections that can be antibiotic resistant but also leading to pyogenic liver abscess (PLA) disease. Armed with knowledge of the chemical structures of K. pneumoniae K1 and K2 surface capsular polysaccharides (CPSs) and their CPS depolymerases from bacteriophages, we developed potential glycoconjugate vaccines against this organism. This was done by using CPS polymerases present in tail spike proteins (TSPs) of specific KP bacteriophages to cleave the CPS and then chemically conjugating the fragment oligosaccharides to carrier proteins.

Indexed as

Bacterial VaccinesCross InfectionGlycoconjugatesKlebsiella InfectionsKlebsiella pneumoniaeAnimalsBacterial CapsulesBacteriophagesHumansLiver Abscess, PyogenicPolysaccharides, BacterialVaccines, ConjugateBacterial VaccinesGlycoconjugatesPolysaccharides, BacterialVaccines, ConjugateAntimicrobial ResistanceBacteriophage depolymeraseCapsular polysaccharideCarbapenem resistanceConjugate vaccineKlebsiella pneumoniaePyogenic Liver Abscess

Identifiers

PMID41917404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.